Endovascular closure of atrial septal defect
KEYWORDS: septal, atrial, atrial septal, defect, procedure, patients, septal defect, closure, atrium, device, right, endovascular, reported, cardiac, defects

out of 334); thrombus formation 0.4% (1 out of 258) to 3% (1 out of 37); brachial plexus injury 3% (1 out of 39); right iliac vein dissection 0.6% (1 out of 159); stroke 0.1% (5 out of 3,460) to 0.3% (1 out of 334); cardiac tamponade 0.1% (2 out of 3,460); cardiac perforation 0.03% (1 out of 3,460); and endocarditis 0.03% (1 out of 3,460). For more details, see the overview. 2.4.2 The Specialist Advisors listed arrhythmias, stroke, device embolisation and cardiac tamponade as potential adverse effects of the procedure. 2.5 Other comments 2.5.1 There is the potential for long-term adverse effects and clinicians should report these to the Medicines and Healthcare products Regulatory Agency (MHRA). 2.5.2 These recommendations were based on evidence on the use of the Amplatzer, CardioSEAL, STARFlex and Helex devices for the endovascular closure of atrial septal defect. NICE may review the procedure if further data relating to other devices become available.
